{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:35:20Z","timestamp":1775255720617,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer Inc"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1093\/rheumatology\/key338","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T07:21:37Z","timestamp":1540279297000},"page":"481-491","source":"Crossref","is-referenced-by-count":21,"title":["Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry"],"prefix":"10.1093","volume":"58","author":[{"given":"Inge C","family":"Olsen","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Lie","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu","family":"Vasilescu","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene","family":"Wallenstein","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander","family":"Strengholt","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Capelle aan den IJssel, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"key":"key\n\t\t\t\t2019022006304953800_key338-B1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B3","doi-asserted-by":"crossref","first-page":"e000262","DOI":"10.1136\/rmdopen-2016-000262","article-title":"Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis","volume":"2","author":"Fleischmann","year":"2016","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B4","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3899\/jrheum.110054","article-title":"Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression","volume":"38","author":"Wells","year":"2011","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/ard.2010.139774","article-title":"Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Soliman","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/keq368","article-title":"Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries","volume":"50","author":"Mariette","year":"2011","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B7","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/ar1933","article-title":"Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low\u2013results from RABBIT, the German biologics register","volume":"8","author":"Listing","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B8","first-page":"2156","article-title":"Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry","volume":"54","author":"J\u00f8rgensen","year":"2015","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B9","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/kev019","article-title":"Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry","volume":"54","author":"Gabay","year":"2015","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","article-title":"TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice","volume":"1173","author":"Marchesoni","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B12","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","article-title":"Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies","volume":"53","author":"Favalli","year":"2014","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B13","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s12272-014-0337-1","article-title":"Comparative effectiveness of cycling of tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-\u03b1 inhibitor using a Bayesian approach","volume":"37","author":"Kim","year":"2014","journal-title":"Arch Pharm Res"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/13696998.2016.1275653","article-title":"Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis","volume":"20","author":"Chastek","year":"2017","journal-title":"J Med Econ"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B15","first-page":"S188","article-title":"A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases","volume":"23","author":"Kvien","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B17","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/ar2745","article-title":"Outcome measures in inflammatory rheumatic diseases","volume":"11","author":"Fransen","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B19","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s10067-013-2281-8","article-title":"Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice","volume":"32","author":"Kaufmann","year":"2013","journal-title":"Clin Rheumatol"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7525-12-102","article-title":"Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs\u2014a systematic review and network meta-analysis","volume":"12","author":"Jansen","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B21","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","article-title":"Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/acr.22108","article-title":"Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity","volume":"66","author":"Tymms","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B23","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2147\/PPA.S117774","article-title":"Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach","volume":"10","author":"Alten","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B24","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/art.22719","article-title":"Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B25","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/art.34543","article-title":"Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity","volume":"64","author":"Studenic","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B26","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1002\/acr.20643","article-title":"Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort","volume":"63","author":"Zhang","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/ard.2007.077503","article-title":"Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis","volume":"67","author":"Heiberg","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B29","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/ard.62.10.944","article-title":"Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study","volume":"62","author":"Aletaha","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40744-017-0073-3","article-title":"Treatment with biologicals in rheumatoid arthritis: an overview","volume":"4","author":"Rein","year":"2017","journal-title":"Rheumatol Ther"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B31","first-page":"i84","article-title":"Comparison of biologic disease-modifying anti-rheumatic drug rheumatoid arthritis treatment dynamics across five European Union countries","volume":"55(Suppl 1)","author":"Taylor","year":"2016","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B32","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B34","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3899\/jrheum.151014","article-title":"Effectiveness of tumor necrosis factor inhibitors in combination with various csDMARD in the treatment of rheumatoid arthritis: data from the DREAM registry","volume":"43","author":"Manders","year":"2016","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/s12891-016-1207-4","article-title":"Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria","volume":"17","author":"Rintelen","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1759720X16665330","article-title":"Combination therapy with biologic agents in rheumatic diseases: current and future prospects","volume":"8","author":"Inui","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/annrheumdis-2017-eular.1939","article-title":"TNFI and tofacitinib monotherapy and comparative effectiveness in clinical practice: results from CORRONA Registry","volume":"76(Suppl 2)","author":"Reed","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B38","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/art.21830","article-title":"Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Hyrich","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022006304953800_key338-B39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/14397595.2017.1325058","article-title":"Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis","volume":"28","author":"Kanbori","year":"2018","journal-title":"Mod Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/3\/481\/27900781\/key338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:14:56Z","timestamp":1775250896000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/3\/481\/5224790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,11,30]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key338","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,11,30]]}}}